Biotech

All Articles

Merck ceases period 3 TIGIT test in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT course has actually suffered yet another setback. Months after shuttering a ...

After a hard year, Exscientia folds up in to Recursion

.After a year defined through pipeline cuts, the departure of its own chief executive officer and al...

Cullinan, after $25M deal, hands back bispecific to Harbour

.Cullinan Rehab was actually blown away sufficient along with Harbour BioMed's bispecific invulnerab...

A closer consider Brutal Biotech's Strong 15

.In this full week's episode of "The Top Pipe," our company are actually diving right into Ferocious...

Lilly encounters period 2 failing of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's gathering celebrating the approval of Alzheim...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of substantial management hirings, firings an...

Lykos are going to inquire FDA to reexamine its decision observing denial of MDMA treatment for trauma

.Following a bad presenting for Lykos Rehabs' MDMA candidate for post-traumatic stress disorder at a...

AN 2 halves head count, stops stage 3 test after records let down

.AN2 Therapies is actually reviewing its own company in response to poor midphase data, vowing to la...

Merck pays $700M for bispecific, spying autoimmune opening and also opportunity to challenge Amgen in cancer

.Merck &amp Co. is spending $700 thousand in advance to test Amgen in a blood cancer cells market. T...

Gilead pays J&ampJ $320M to go out licensing offer for seladelpar

.Along With Gilead Sciences almost an FDA selection for its own liver condition medicine seladelpar,...